You are here: Home / Protocols / Evaluation of emerging tissue-based biomarkers for aggressive prostate cancer in men on active surveillance

Evaluation of emerging tissue-based biomarkers for aggressive prostate cancer in men on active surveillance

Feng, ZidingFred Hutchinson Cancer Research Center
Prostate and Urologic Cancers Research Group

This work is being done as part of the funded NIH grant entitled Precision Medicine Approach to Prostate Cancer Active Surveillance (R01 CA184712; PD-PIs Mark A. Rubin and Daniel W. Lin). Emerging data from DNA sequencing of prostate cancer have nominated non-ETS fusions involving the RAF pathway and novel recurrent mutations such as SPOP. In this study we will incorporate the most promising recurrent mutations from multiple sequencing studies into a focused DNA-based Next Generation Sequencing Assay that takes advantage of the archival biopsy samples from the PASS cohort.

This is a sub-project of the GHI Collaboration Project (PASS Project Reference Set ID 417). The Prostate Active Surveillance Study Consortium (PASS) will provide approximately 715 formalin-fixed paraffin-embedded diagnostic biopsy specimens to Genomic Health, Inc. (GHI) for use in the collaborative study entitled “Molecular Markers for the Prediction of Disease Progression in Men with Clinically Localized Prostate Cancer on Surveillance in the Canary Prostate Active Surveillance Study (PASS)” (the “PASS GHI Study”). Specimens will be shipped to GHI in batches of 50. For the conduct of the PASS GHI Study, 8 x 5µm tumor sections will be made from the formalin-fixed paraffin-embedded biopsy specimens For the research study described here an additional 7 × 5µm sections will be made from the same tumor blocks used to isolate RNA for Oncotype DX validation. These additional sections will be used for the extraction of tumor DNA. Manual dissection may be used to enrich for tumor tissue followed by DNA extraction, both performed at GHI. All extracted tumor DNA will be sent from GHI to Dr. Mark Rubin at Weill Cornell Medical College (WCMC) for evaluation of novel tissue-based biomarkers for prediction of aggressive prostate cancer, Aim 2 of Dr. Rubin’s grant listed above. The research results from Dr. Rubin’s work will be analyzed with the PASS clinical data at the PASS Data Management and Coordinating Center located at the Fred Hutchinson Cancer Research Center.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

Announcement 01/27/2020

Please visit the EDRN Registration page for registration/hotel information for the 35th EDRN Steering Committee Meeting from March 31-April 2, 2020, in Tempe, AZ.

This icon signifies that something is happening and we kindly ask you to please wait